Results 11 to 20 of about 131,254 (306)
ImmunoMedicine, 2022 Acute myeloid leukemia (AML) is one of the lethal hematological malignancies with high relapse rates and poor prognosis. Since chimeric antigen receptor cellular therapy has exhibited remarkable therapeutic outcomes in B‐cell malignancies, many studies ...
Yue Huang, Mi Shao, Yiyun Wang, He Huang
doaj +2 more sources
Tumor Biology, 2017 Chimeric antigen receptor modified T cell–based immunotherapy is revolutionizing the field of cancer treatment. However, its potential in treating bile duct carcinoma has not been fully explored.
Jie-Ying Xu +9 more
doaj +2 more sources
Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity
Signal Transduction and Targeted Therapy, 2023 Ligand-induced receptor dimerization or oligomerization is a widespread mechanism for ensuring communication specificity, safeguarding receptor activation, and facilitating amplification of signal transduction across the cellular membrane.
Yan Sun +15 more
doaj +2 more sources
Chimeric antigen receptor–engineered T cells for liver cancers, progress and obstacles
Tumor Biology, 2017 Chimeric antigen receptor–engineered T cells therapy has become the hottest topic of immunotherapy, as its great successes achieved in treating refractory hematological malignancies.
Keyu Li +3 more
doaj +2 more sources
Haematologica, 2016 Adoptive transfer of chimeric antigen receptor-transduced T cells is a promising strategy for cancer immunotherapy. The CD38 molecule, with its high expression on multiple myeloma cells, appears a suitable target for antibody therapy.
Esther Drent +13 more
doaj +3 more sources
Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
Mediterranean Journal of Hematology and Infectious Diseases, 2021 Chimeric antigen receptor (CAR) T cells represent one of the newest frontiers of cell therapy. Their application currently involves relapsed/refractory aggressive B cell lymphoma and leukemia as a standard of care, while several studies are exploring CAR-
Eugenio Galli +10 more
doaj +3 more sources
Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells [PDF]
CPT: Pharmacometrics & Systems Pharmacology, 2019 Tisagenlecleucel is a chimeric antigen receptor–T cell therapy that facilitates the killing of CD19+ B cells. A model was developed for the kinetics of tisagenlecleucel and the impact of therapies for treating cytokine release syndrome (tocilizumab and ...
Andrew M. Stein +15 more
doaj +2 more sources
Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic [PDF]
, 2021 Chimeric antigen receptor (CAR) T cells have emerged as an effective therapy for patients with relapsed and refractory haematological malignancies. However, there are many challenges preventing clinical efficacy and thus broader translation of this ...
Caitlin R Hopkins, Joseph A Fraietta
core +1 more source
Critical Care Explorations, 2021 BACKGROUND:. Chimeric antigen receptor T-cell therapies (CAR-T) are transforming the treatment of B-cell leukemias and lymphomas. Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome represent common, potentially life ...
Kai Singbartl, MD, MPH +4 more
doaj +1 more source
Chimeric antigen receptors that trigger phagocytosis [PDF]
eLife, 2018 Abstract Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T cells to kill cancer. The success of CAR-T cell therapies highlights the promise of programmed immunity, and suggests that applying CAR strategies to other immune cell lineages may be beneficial. Here, we engineered a family of Chimeric Antigen Receptors
Meghan A Morrissey +6 more
openaire +5 more sources